ATAI
phase a efficacy data symbol coding category fluency data confirmed activity in schizophrenia population improved dose dependent widespread changes observed across brain regions symbol coding day day increased alpha middle high doses decreased beta dose observed elevations in resting state alpha increased and decreased suggesting a relaxed wakeful state without drowsiness at the mid to high dose levels has previously shown pro cognitive effects human clinical studies study showed wide spread beneficial | ATAI
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
35 of 41
Related slides by other companies
Oculis
Investor Presentation
July 2023
study overview | Oculis
GH Research
Investor Presentation
March 2023
and observed improved outcome in phase phase single dose | GH Research
GH Research
Investor Presentation
May 2023
and observed improved outcome in phase phase single dose | GH Research
Adagio Therapeutics
Investor Conference
June 2023
ongoing phase trial of with initial data planned for | Adagio Therapeutics
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io